Knight Therapeutics (OTCMKTS:KHTRF) Trading Down 0.9% – Should You Sell?

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares traded down 0.9% during mid-day trading on Thursday . The stock traded as low as $6.89 and last traded at $6.8940. Approximately 6,276 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 8,267 shares. The stock had previously closed at $6.96.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Knight Therapeutics in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Knight Therapeutics currently has a consensus rating of “Buy”.

Knight Therapeutics Stock Down 0.9%

The stock has a 50 day simple moving average of $6.57 and a two-hundred day simple moving average of $5.46.

About Knight Therapeutics

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.